Kinetics and viral protein specificity of the cytotoxic t lymphocyte response in healthy adults immunized with live attenuated varicella vaccine

Journal of Infectious Diseases

Volumn 165, Issue 5, 1992, Pages 852-858

  Sharp, Margaret ^a,b   Terada, Kehei ^a,b,c   Wilson, Alexandra ^a,b   Nader, Sonia ^a,b   Kinchington, Paul E ^a,b,d   Ruyechan, William T ^a,b   Hay, John ^a,b   Arvin, Ann M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHICKENPOX VACCINE; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ADULT; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNITY; KINETICS; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VARICELLA ZOSTER VIRUS;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; HERPESVIRUS 3, HUMAN; HUMAN; IMMUNITY, CELLULAR; KINETICS; LYMPHOCYTE ACTIVATION; RANDOM ALLOCATION; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0026568782     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/165.5.852     Document Type: Article

References (27)

1. Patel PA, Yoonessi S, O'Malley J, Freeman A, Gershon A, Ogra PL. Cell-mediated immunity to varicella zoster virus infection in subjects with lymphoma or leukaemia. J Pediatr 1979;94:223-30.
2. Arvin AM, Koropchak CM, Williams BRG, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 1986; 154:422-9.
3. Hayward AR, Herberger M. Lymphocyte responses to varicella-zoster virus in the elderly. J Clin Immunol 1987;7:174-8.
4. Miller AE. Selective decline in cellular immune response to varicella zoster in the elderly. Neurology 1980;30:582-7.
5. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-7.
6. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in lymphoma patients. J Clin Invest 1980;65:869-78.
7. Sorenson OS, Haahr S, Moller-Larson A, WildenhoffK. Cell mediated and humoral immunity to herpes viruses during and after herpes zoster infections. Infect Immun 1980;29:369-75.
8. Hayes FA, Feldman S. Cell-mediated immunity to varicella zoster virus in children being treated for cancer. Cancer 1978;42:159-63.
9. Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(suppl):748-56.
10. Gershon AA, Steinber SP, Gelb L, et al. Live attenuated varicella vaccine: efficacy for children with leukemia. JAMA 1984;252:355-62.
11. Watson B, Keller PM, Ellis RW, Starr SE. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 1990; 162:794-9.
12. Kinchington PR, Houghland JK, Arvin AM, Ruyechan WT, Hay J. Varicella zoster virus IE62 protein is a major virion component. J Virol 1992;66:359-66.
13. Giller RH, Winistorfer S, Grose C. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis 1989; 160:919-28.
14. Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis 1990;162:1049-54.
15. Diaz PS, Smith S, Hunter E, Arvin AM. T-Iymphocyte cytotoxicity with natural varicella zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989; 142:636.
16. Arvin AM, Sharp MS, Smith S, et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T-lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 1991;146:257-64.
17. Lowry PW, Solem S, Watson BN, et al. Immunity in strain 2 guinea pigs inoculated with vaccinia recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the immediate early gene 62. J Gen Virol 1992 (in press).
18. Kinchington PR, Reminick J, Ostrove J, Strauss SE, Ruyechan WT, Hay J. A putative glycoprotein gene of varicella zoster virus with variable copy number of a 42bp repeat sequence has homology to herpes simplex virus glycoprotein C. J Virol 1986;59:660-8.
19. Gershon AA, Steinberg SP, La Russa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132-7.
20. Diaz PS, Smith S, Hunter E, Arvin AM. Immunity to varicella-zoster virus antigen, glycoprotein I (gp I) and a non-glycosylated protein (p 170): relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis 1988;158:1245-52.
21. Fazekas de. Groth S. The evaluation of limiting dilution assays. J Immunol Methods 1982;49:1211-40.
22. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Human T-cells recognize multiple epitopes of a major tegument/immediate early protein (IE62) and glycoprotein I of varicella-zoster virus. Viral Immunol 1992;4:151-66.
23. Arvin AM, Kinney-Thomas E, Shriver K, et al. Immunity to varicella-zoster viral glycoproteins gp I (90/58) and gp III (gp 118) and to a nonglycosylated protein, p170. J ImmunoI 1986; 137:1346-51.
24. Hayward AR, Herberger MJ, Groothuis J, Levin MR. Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus. J Immunol 1984; 133:2469-73.
25. Hayward A. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol 1990;64:651-5.
26. Kinchington PR, Ling P, Pensiero M, Moss B, Ruyechan WT, Hay J. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J Virol 1990;64:4540-8.
27. Hayward A, Levin M, Wolf A, Gilden D. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991;163:873-5.